Another collaboration to explore combination of Opdivo, now with IPI-549

9 November 2016

A clinical trial collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in patients with advanced solid tumors, the makers of the respective drugs – Bristol-Myers Squibb (NYSE: BMY) and Infinity Pharmaceuticals (Nasdaq: INFI) – revealed today.

This deal, the financial terms of which were not disclosed, adds to the long list of deals for combination trials of Bristol-Myers’ blockbuster cancer drug Opdivo, including with AbbVie’s Rova-T (rovalpituzumab tesirine), Janssen's investigational immunotherapy JNJ-64041757, Innate Pharma’s lirilumab, Nektar Therapeutics’ NKTR-214 and PsiOxus Therapeutics’ enadenotucirev.

The dose-escalation portion exploring IPI-549 as a monotherapy in Infinity's Phase I study is continuing, and the first dose-escalation cohort studying IPI-549 in combination with Opdivo, a PD-1 immune checkpoint inhibitor, is expected to begin this fall. IPI-549 is an oral immuno-oncology development candidate that is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma and is the only investigational PI3K-gamma inhibitor in clinical development.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK